Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial

Recruiting now · Phase 2

Conditions studied: Lipid Disorder, Hypercholesterolemia, Cardiovascular Diseases, Atherosclerosis

In brief

Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) is a protocolized intervention based on American College of Cardiology/American Heart Association and US Preventive Services Task Force guidelines designed to initiate preventive cardiovascular care for emergency department patients being evaluated for acute coronary syndrome. The overarching goals of this proposal are to (1) determine the efficacy of EMERALD at lowering low-density lipoprotein cholesterol (LDL-C) and non high-density lipoprotein cholesterol (non-HDL-C) among at-risk Emergency Department (ED) patients who are not already receiving guideline-directed outpatient preventive care and (2) inform our understanding of patient adherence and determinants of implementation for ED-based cardiovascular disease prevention strategies.

Key facts

Study ID

NCT06488105

Run by

Wake Forest University Health Sciences

People needed

130

Starts

2024-08-05

Expected to finish

2029-03-31

Last updated by the study team

2026-02-27

Who can join

Age: 40 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Evaluation for Acute Coronary Syndrome
• Age 40-75 Years
• 10-year Atherosclerotic Cardiovascular Disease (ASCVD) Risk ≥7.5% or Known Diabetes or
• Known ASCVD:
• Myocardial Infarction
• Unstable Angina
• Percutaneous Coronary Intervention
• Coronary Artery Bypass Graft
• Stroke
• Transient Ischemic Attack
• Peripheral Artery Disease

You may not qualify if…

• ST-Segment Elevation Myocardial Infarction (STEMI) Activation
• ST Depression >1 mm in Contiguous Leads
• On a Lipid Lowering Agent (Statin, PCSK9 Inhibitor, Bempedoic Acid, Ezetimibe, Inclisiran, etc.)
• Inability to Return for 30-day Follow-up
• Unstable Vitals (Systolic blood pressure <90, HR >120 or <50, oxygen saturation <90%)
• Statin Intolerance
• Any Resulted High-Sensitivity Troponin I ≥100 ng/L
• End-stage renal disease (ESRD) and/or glomerular filtration rate (GFR) <30 mL/min/1.73 m2
• Liver Cirrhosis
• Pregnancy
• Anticipated Hospitalization
• Life Expectancy <1 Year
• Transfer from Another Hospital
• Prisoner
• Non-English Speaking

Where it is running

• Wake Forest University Health Sciences — Winston-Salem, North Carolina, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.